Cholesterol & Lipid Lowering

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Simvastatin Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Simvastatin Tablets 20mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Fenofibrate Tablets 160 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Fenofibrate Tablets 145 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Saroglitazar Tablets 4mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Telmisartan and Statin (Rosuvastatin or Atorvastatin) is a dual cardio-metabolic polypill formulation uniting an ARB with an HMG-CoA reductase inhibitor. Telmisartan controls systemic blood pressure and improves vascular endothelial function, while the statin potently reduces hepatic cholesterol synthesis, lowering LDL-C and apolipoprotein B while stabilizing atherosclerotic plaques. Indicated for co-existing essential hypertension and hyperlipidemia/dyslipidemia to mitigate cardiovascular morbidity and stroke.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Cod liver oil 300MG + Evening primrose oil 300MG + Omega-3 fatty acid 90MG + Vitamin E 10MG Soft Gelatin Capsules is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Fenofibrate Capsules 200mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Bempedoic Acid is an oral, first-in-class non-statin adenosine triphosphate-citrate lyase (ACL) inhibitor. It acts upstream of HMG-CoA reductase in the hepatic cholesterol biosynthesis pathway. Because it is a prodrug requiring activation by very long-chain acyl-CoA synthetase-1 (ACSVL1), an enzyme present exclusively in the liver and absent in skeletal muscle, it inhibits cholesterol synthesis without causing the myopathy and muscle pain common to statins. Indicated for primary hyperlipidemia and to reduce cardiovascular risk in patients with atherosclerotic cardiovascular disease who are statin-intolerant.

Statin and Fenofibrate is a comprehensive dual-action lipid-regulating combination. The statin (Atorvastatin or Rosuvastatin) competitively inhibits HMG-CoA reductase, potently lowering LDL cholesterol and apolipoprotein B, while fenofibrate, a fibric acid derivative, activates peroxisome proliferator-activated receptor-alpha (PPAR-alpha), dramatically reducing triglycerides (by 30-50%), increasing HDL cholesterol, and converting atherogenic small dense LDL into larger buoyant particles. Indicated for mixed dyslipidemia, severe hypertriglyceridemia, and diabetic dyslipidemia.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Ezetimibe Tablets 10mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Ezetimibe Tablets 5mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

HMG-CoA Reductase Inhibitor (Statin) on the WHO Model List of Essential Medicines. It competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, the rate-limiting enzyme in cholesterol biosynthesis, upregulating hepatic LDL receptors and drastically clearing circulating atherogenic LDL-C, VLDL, and triglycerides while increasing HDL-C and stabilizing atherosclerotic plaques. Indicated for primary hypercholesterolemia, mixed dyslipidemia, and primary/secondary prevention of cardiovascular events (myocardial infarction, stroke, revascularization).

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Statin and Ezetimibe is an intensive dual-pathway LDL-lowering formulation. The statin inhibits endogenous cholesterol biosynthesis in the liver, while ezetimibe selectively inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the intestinal brush border, blocking absorption of dietary and biliary cholesterol. This dual mechanism achieves up to 65% reduction in LDL cholesterol without requiring high-dose statin monotherapy. Indicated for primary hyperlipidemia, familial hypercholesterolemia, and high-risk atherosclerotic cardiovascular disease.

Telmisartan and Statin (Rosuvastatin or Atorvastatin) is a dual cardio-metabolic polypill formulation uniting an ARB with an HMG-CoA reductase inhibitor. Telmisartan controls systemic blood pressure and improves vascular endothelial function, while the statin potently reduces hepatic cholesterol synthesis, lowering LDL-C and apolipoprotein B while stabilizing atherosclerotic plaques. Indicated for co-existing essential hypertension and hyperlipidemia/dyslipidemia to mitigate cardiovascular morbidity and stroke.